0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Peptide Drug CDMO Market Research Report 2026
Published Date: 2026-01-28
|
Report Code: QYRE-Auto-17Z18878
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Peptide Drug CDMO Market Research Report 2024
BUY CHAPTERS

Global Peptide Drug CDMO Market Research Report 2026

Code: QYRE-Auto-17Z18878
Report
2026-01-28
Pages:111
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Peptide Drug CDMO Market Size

The global Peptide Drug CDMO market was valued at US$ 3010 million in 2025 and is anticipated to reach US$ 5842 million by 2032, at a CAGR of 10.1% from 2026 to 2032.

Peptide Drug CDMO Market

Peptide Drug CDMO Market

Peptide CDMO refers to an organization that accepts commissions from pharmaceutical companies and engages in the development and production of peptide drugs. These organizations usually have advanced peptide synthesis, purification, analysis and other technologies, and can provide customers with one-stop services from peptide API synthesis, purification, structural identification to formulation development, clinical trials, etc.
As a unique drug compound, peptides are between small molecules and proteins, and are different in biochemistry and treatment. Peptides provide opportunities for therapeutic interventions that closely mimic natural pathways and play a major role in various physiological processes in the human body (including hormones, neurotransmitters) or in inflammatory responses. Peptide drugs have the characteristics of strong selectivity and rapid onset, and can be extracted naturally or synthesized artificially. With multiple advantages such as high purity and controllable quality, they have become popular drugs at present. The medical field is an important application market for peptide substances, and the market demand for peptide drugs is increasing. Based on the complexity and high-tech characteristics of peptide drug development, peptide development and production outsourcing services came into being, that is, peptide CDMO began to appear.
The North American market for Peptide Drug CDMO is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for Peptide Drug CDMO is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The global market for Peptide Drug CDMO in Antineoplastic Drugs is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 to 2032.
Major global companies of Peptide Drug CDMO include Bachem, PolyPeptide, CordenPharma, AmbioPharm, USV Peptides, Thermofischer, Bio Basic, JPT, Genscript, Xinbang Pharma, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global Peptide Drug CDMO market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Peptide Drug CDMO. The Peptide Drug CDMO market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Peptide Drug CDMO market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Peptide Drug CDMO manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation

Scope of Peptide Drug CDMO Market Report

Report Metric Details
Report Name Peptide Drug CDMO Market
Accounted market size in 2025 US$ 3010 million
Forecasted market size in 2032 US$ 5842 million
CAGR 10.1%
Base Year 2025
Forecasted years 2026 - 2032
Segment by Type
  • APIs and Intermediates
  • FDF
Segment by Application
  • Antineoplastic Drugs
  • Geno-Urinary System and Sex Hormones
  • Cardiovascular System Drugs
  • Anti-Infective Drugs
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Bachem, PolyPeptide, CordenPharma, AmbioPharm, USV Peptides, Thermofischer, Bio Basic, JPT, Genscript, Xinbang Pharma, ScinoPharm, SN Biopharm, CBL, Piramal Pharma, CPC Scientific
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
  • Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
  • Chapter 3: Provides a detailed view of the competitive landscape for Peptide Drug CDMO companies, covering revenue share, development plans, and mergers and acquisitions.
  • Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
  • Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
  • Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
  • Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
  • Chapter 12: Key findings and conclusions of the report.

FAQ for this report

How fast is Peptide Drug CDMO Market growing?

Ans: The Peptide Drug CDMO Market witnessing a CAGR of 10.1% during the forecast period 2026-2032.

What is the Peptide Drug CDMO Market size in 2032?

Ans: The Peptide Drug CDMO Market size in 2032 will be US$ 5842 million.

Who are the main players in the Peptide Drug CDMO Market report?

Ans: The main players in the Peptide Drug CDMO Market are Bachem, PolyPeptide, CordenPharma, AmbioPharm, USV Peptides, Thermofischer, Bio Basic, JPT, Genscript, Xinbang Pharma, ScinoPharm, SN Biopharm, CBL, Piramal Pharma, CPC Scientific

What are the Application segmentation covered in the Peptide Drug CDMO Market report?

Ans: The Applications covered in the Peptide Drug CDMO Market report are Antineoplastic Drugs, Geno-Urinary System and Sex Hormones, Cardiovascular System Drugs, Anti-Infective Drugs

What are the Type segmentation covered in the Peptide Drug CDMO Market report?

Ans: The Types covered in the Peptide Drug CDMO Market report are APIs and Intermediates, FDF

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Peptide Drug CDMO Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 APIs and Intermediates
1.2.3 FDF
1.3 Market by Application
1.3.1 Global Peptide Drug CDMO Market Growth by Application: 2021 vs 2025 vs 2032
1.3.2 Antineoplastic Drugs
1.3.3 Geno-Urinary System and Sex Hormones
1.3.4 Cardiovascular System Drugs
1.3.5 Anti-Infective Drugs
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Peptide Drug CDMO Market Perspective (2021–2032)
2.2 Global Peptide Drug CDMO Growth Trends by Region
2.2.1 Global Peptide Drug CDMO Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Peptide Drug CDMO Historic Market Size by Region (2021–2026)
2.2.3 Peptide Drug CDMO Forecasted Market Size by Region (2027–2032)
2.3 Peptide Drug CDMO Market Dynamics
2.3.1 Peptide Drug CDMO Industry Trends
2.3.2 Peptide Drug CDMO Market Drivers
2.3.3 Peptide Drug CDMO Market Challenges
2.3.4 Peptide Drug CDMO Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Peptide Drug CDMO Players by Revenue
3.1.1 Global Top Peptide Drug CDMO Players by Revenue (2021–2026)
3.1.2 Global Peptide Drug CDMO Revenue Market Share by Players (2021–2026)
3.2 Global Top Peptide Drug CDMO Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Peptide Drug CDMO Revenue
3.4 Global Peptide Drug CDMO Market Concentration Ratio
3.4.1 Global Peptide Drug CDMO Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Peptide Drug CDMO Revenue in 2025
3.5 Global Key Players of Peptide Drug CDMO Head Offices and Areas Served
3.6 Global Key Players of Peptide Drug CDMO, Products and Applications
3.7 Global Key Players of Peptide Drug CDMO, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 Peptide Drug CDMO Breakdown Data by Type
4.1 Global Peptide Drug CDMO Historic Market Size by Type (2021–2026)
4.2 Global Peptide Drug CDMO Forecasted Market Size by Type (2027–2032)
5 Peptide Drug CDMO Breakdown Data by Application
5.1 Global Peptide Drug CDMO Historic Market Size by Application (2021–2026)
5.2 Global Peptide Drug CDMO Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America Peptide Drug CDMO Market Size (2021–2032)
6.2 North America Peptide Drug CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Peptide Drug CDMO Market Size by Country (2021–2026)
6.4 North America Peptide Drug CDMO Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Peptide Drug CDMO Market Size (2021–2032)
7.2 Europe Peptide Drug CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Peptide Drug CDMO Market Size by Country (2021–2026)
7.4 Europe Peptide Drug CDMO Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Peptide Drug CDMO Market Size (2021–2032)
8.2 Asia-Pacific Peptide Drug CDMO Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Peptide Drug CDMO Market Size by Region (2021–2026)
8.4 Asia-Pacific Peptide Drug CDMO Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Peptide Drug CDMO Market Size (2021–2032)
9.2 Latin America Peptide Drug CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Peptide Drug CDMO Market Size by Country (2021–2026)
9.4 Latin America Peptide Drug CDMO Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Peptide Drug CDMO Market Size (2021–2032)
10.2 Middle East & Africa Peptide Drug CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Peptide Drug CDMO Market Size by Country (2021–2026)
10.4 Middle East & Africa Peptide Drug CDMO Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Bachem
11.1.1 Bachem Company Details
11.1.2 Bachem Business Overview
11.1.3 Bachem Peptide Drug CDMO Introduction
11.1.4 Bachem Revenue in Peptide Drug CDMO Business (2021–2026)
11.1.5 Bachem Recent Development
11.2 PolyPeptide
11.2.1 PolyPeptide Company Details
11.2.2 PolyPeptide Business Overview
11.2.3 PolyPeptide Peptide Drug CDMO Introduction
11.2.4 PolyPeptide Revenue in Peptide Drug CDMO Business (2021–2026)
11.2.5 PolyPeptide Recent Development
11.3 CordenPharma
11.3.1 CordenPharma Company Details
11.3.2 CordenPharma Business Overview
11.3.3 CordenPharma Peptide Drug CDMO Introduction
11.3.4 CordenPharma Revenue in Peptide Drug CDMO Business (2021–2026)
11.3.5 CordenPharma Recent Development
11.4 AmbioPharm
11.4.1 AmbioPharm Company Details
11.4.2 AmbioPharm Business Overview
11.4.3 AmbioPharm Peptide Drug CDMO Introduction
11.4.4 AmbioPharm Revenue in Peptide Drug CDMO Business (2021–2026)
11.4.5 AmbioPharm Recent Development
11.5 USV Peptides
11.5.1 USV Peptides Company Details
11.5.2 USV Peptides Business Overview
11.5.3 USV Peptides Peptide Drug CDMO Introduction
11.5.4 USV Peptides Revenue in Peptide Drug CDMO Business (2021–2026)
11.5.5 USV Peptides Recent Development
11.6 Thermofischer
11.6.1 Thermofischer Company Details
11.6.2 Thermofischer Business Overview
11.6.3 Thermofischer Peptide Drug CDMO Introduction
11.6.4 Thermofischer Revenue in Peptide Drug CDMO Business (2021–2026)
11.6.5 Thermofischer Recent Development
11.7 Bio Basic
11.7.1 Bio Basic Company Details
11.7.2 Bio Basic Business Overview
11.7.3 Bio Basic Peptide Drug CDMO Introduction
11.7.4 Bio Basic Revenue in Peptide Drug CDMO Business (2021–2026)
11.7.5 Bio Basic Recent Development
11.8 JPT
11.8.1 JPT Company Details
11.8.2 JPT Business Overview
11.8.3 JPT Peptide Drug CDMO Introduction
11.8.4 JPT Revenue in Peptide Drug CDMO Business (2021–2026)
11.8.5 JPT Recent Development
11.9 Genscript
11.9.1 Genscript Company Details
11.9.2 Genscript Business Overview
11.9.3 Genscript Peptide Drug CDMO Introduction
11.9.4 Genscript Revenue in Peptide Drug CDMO Business (2021–2026)
11.9.5 Genscript Recent Development
11.10 Xinbang Pharma
11.10.1 Xinbang Pharma Company Details
11.10.2 Xinbang Pharma Business Overview
11.10.3 Xinbang Pharma Peptide Drug CDMO Introduction
11.10.4 Xinbang Pharma Revenue in Peptide Drug CDMO Business (2021–2026)
11.10.5 Xinbang Pharma Recent Development
11.11 ScinoPharm
11.11.1 ScinoPharm Company Details
11.11.2 ScinoPharm Business Overview
11.11.3 ScinoPharm Peptide Drug CDMO Introduction
11.11.4 ScinoPharm Revenue in Peptide Drug CDMO Business (2021–2026)
11.11.5 ScinoPharm Recent Development
11.12 SN Biopharm
11.12.1 SN Biopharm Company Details
11.12.2 SN Biopharm Business Overview
11.12.3 SN Biopharm Peptide Drug CDMO Introduction
11.12.4 SN Biopharm Revenue in Peptide Drug CDMO Business (2021–2026)
11.12.5 SN Biopharm Recent Development
11.13 CBL
11.13.1 CBL Company Details
11.13.2 CBL Business Overview
11.13.3 CBL Peptide Drug CDMO Introduction
11.13.4 CBL Revenue in Peptide Drug CDMO Business (2021–2026)
11.13.5 CBL Recent Development
11.14 Piramal Pharma
11.14.1 Piramal Pharma Company Details
11.14.2 Piramal Pharma Business Overview
11.14.3 Piramal Pharma Peptide Drug CDMO Introduction
11.14.4 Piramal Pharma Revenue in Peptide Drug CDMO Business (2021–2026)
11.14.5 Piramal Pharma Recent Development
11.15 CPC Scientific
11.15.1 CPC Scientific Company Details
11.15.2 CPC Scientific Business Overview
11.15.3 CPC Scientific Peptide Drug CDMO Introduction
11.15.4 CPC Scientific Revenue in Peptide Drug CDMO Business (2021–2026)
11.15.5 CPC Scientific Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
 Table 1. Global Peptide Drug CDMO Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
 Table 2. Key Players of APIs and Intermediates
 Table 3. Key Players of FDF
 Table 4. Global Peptide Drug CDMO Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
 Table 5. Global Peptide Drug CDMO Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 6. Global Peptide Drug CDMO Market Size by Region (US$ Million), 2021–2026
 Table 7. Global Peptide Drug CDMO Market Share by Region (2021–2026)
 Table 8. Global Peptide Drug CDMO Forecasted Market Size by Region (US$ Million), 2027–2032
 Table 9. Global Peptide Drug CDMO Market Share by Region (2027–2032)
 Table 10. Peptide Drug CDMO Market Trends
 Table 11. Peptide Drug CDMO Market Drivers
 Table 12. Peptide Drug CDMO Market Challenges
 Table 13. Peptide Drug CDMO Market Restraints
 Table 14. Global Peptide Drug CDMO Revenue by Players (US$ Million), 2021–2026
 Table 15. Global Peptide Drug CDMO Market Share by Players (2021–2026)
 Table 16. Global Top Peptide Drug CDMO Players by Tier (Tier 1, Tier 2, and Tier 3), based on Peptide Drug CDMO Revenue, 2025
 Table 17. Ranking of Global Top Peptide Drug CDMO Companies by Revenue (US$ Million) in 2025
 Table 18. Global 5 Largest Players Market Share by Peptide Drug CDMO Revenue (CR5 and HHI), 2021–2026
 Table 19. Global Key Players of Peptide Drug CDMO, Headquarters and Area Served
 Table 20. Global Key Players of Peptide Drug CDMO, Products and Applications
 Table 21. Global Key Players of Peptide Drug CDMO, Date of General Availability (GA)
 Table 22. Mergers and Acquisitions, Expansion Plans
 Table 23. Global Peptide Drug CDMO Market Size by Type (US$ Million), 2021–2026
 Table 24. Global Peptide Drug CDMO Revenue Market Share by Type (2021–2026)
 Table 25. Global Peptide Drug CDMO Forecasted Market Size by Type (US$ Million), 2027–2032
 Table 26. Global Peptide Drug CDMO Revenue Market Share by Type (2027–2032)
 Table 27. Global Peptide Drug CDMO Market Size by Application (US$ Million), 2021–2026
 Table 28. Global Peptide Drug CDMO Revenue Market Share by Application (2021–2026)
 Table 29. Global Peptide Drug CDMO Forecasted Market Size by Application (US$ Million), 2027–2032
 Table 30. Global Peptide Drug CDMO Revenue Market Share by Application (2027–2032)
 Table 31. North America Peptide Drug CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 32. North America Peptide Drug CDMO Market Size by Country (US$ Million), 2021–2026
 Table 33. North America Peptide Drug CDMO Market Size by Country (US$ Million), 2027–2032
 Table 34. Europe Peptide Drug CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 35. Europe Peptide Drug CDMO Market Size by Country (US$ Million), 2021–2026
 Table 36. Europe Peptide Drug CDMO Market Size by Country (US$ Million), 2027–2032
 Table 37. Asia-Pacific Peptide Drug CDMO Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 38. Asia-Pacific Peptide Drug CDMO Market Size by Region (US$ Million), 2021–2026
 Table 39. Asia-Pacific Peptide Drug CDMO Market Size by Region (US$ Million), 2027–2032
 Table 40. Latin America Peptide Drug CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 41. Latin America Peptide Drug CDMO Market Size by Country (US$ Million), 2021–2026
 Table 42. Latin America Peptide Drug CDMO Market Size by Country (US$ Million), 2027–2032
 Table 43. Middle East & Africa Peptide Drug CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 44. Middle East & Africa Peptide Drug CDMO Market Size by Country (US$ Million), 2021–2026
 Table 45. Middle East & Africa Peptide Drug CDMO Market Size by Country (US$ Million), 2027–2032
 Table 46. Bachem Company Details
 Table 47. Bachem Business Overview
 Table 48. Bachem Peptide Drug CDMO Product
 Table 49. Bachem Revenue in Peptide Drug CDMO Business (US$ Million), 2021–2026
 Table 50. Bachem Recent Development
 Table 51. PolyPeptide Company Details
 Table 52. PolyPeptide Business Overview
 Table 53. PolyPeptide Peptide Drug CDMO Product
 Table 54. PolyPeptide Revenue in Peptide Drug CDMO Business (US$ Million), 2021–2026
 Table 55. PolyPeptide Recent Development
 Table 56. CordenPharma Company Details
 Table 57. CordenPharma Business Overview
 Table 58. CordenPharma Peptide Drug CDMO Product
 Table 59. CordenPharma Revenue in Peptide Drug CDMO Business (US$ Million), 2021–2026
 Table 60. CordenPharma Recent Development
 Table 61. AmbioPharm Company Details
 Table 62. AmbioPharm Business Overview
 Table 63. AmbioPharm Peptide Drug CDMO Product
 Table 64. AmbioPharm Revenue in Peptide Drug CDMO Business (US$ Million), 2021–2026
 Table 65. AmbioPharm Recent Development
 Table 66. USV Peptides Company Details
 Table 67. USV Peptides Business Overview
 Table 68. USV Peptides Peptide Drug CDMO Product
 Table 69. USV Peptides Revenue in Peptide Drug CDMO Business (US$ Million), 2021–2026
 Table 70. USV Peptides Recent Development
 Table 71. Thermofischer Company Details
 Table 72. Thermofischer Business Overview
 Table 73. Thermofischer Peptide Drug CDMO Product
 Table 74. Thermofischer Revenue in Peptide Drug CDMO Business (US$ Million), 2021–2026
 Table 75. Thermofischer Recent Development
 Table 76. Bio Basic Company Details
 Table 77. Bio Basic Business Overview
 Table 78. Bio Basic Peptide Drug CDMO Product
 Table 79. Bio Basic Revenue in Peptide Drug CDMO Business (US$ Million), 2021–2026
 Table 80. Bio Basic Recent Development
 Table 81. JPT Company Details
 Table 82. JPT Business Overview
 Table 83. JPT Peptide Drug CDMO Product
 Table 84. JPT Revenue in Peptide Drug CDMO Business (US$ Million), 2021–2026
 Table 85. JPT Recent Development
 Table 86. Genscript Company Details
 Table 87. Genscript Business Overview
 Table 88. Genscript Peptide Drug CDMO Product
 Table 89. Genscript Revenue in Peptide Drug CDMO Business (US$ Million), 2021–2026
 Table 90. Genscript Recent Development
 Table 91. Xinbang Pharma Company Details
 Table 92. Xinbang Pharma Business Overview
 Table 93. Xinbang Pharma Peptide Drug CDMO Product
 Table 94. Xinbang Pharma Revenue in Peptide Drug CDMO Business (US$ Million), 2021–2026
 Table 95. Xinbang Pharma Recent Development
 Table 96. ScinoPharm Company Details
 Table 97. ScinoPharm Business Overview
 Table 98. ScinoPharm Peptide Drug CDMO Product
 Table 99. ScinoPharm Revenue in Peptide Drug CDMO Business (US$ Million), 2021–2026
 Table 100. ScinoPharm Recent Development
 Table 101. SN Biopharm Company Details
 Table 102. SN Biopharm Business Overview
 Table 103. SN Biopharm Peptide Drug CDMO Product
 Table 104. SN Biopharm Revenue in Peptide Drug CDMO Business (US$ Million), 2021–2026
 Table 105. SN Biopharm Recent Development
 Table 106. CBL Company Details
 Table 107. CBL Business Overview
 Table 108. CBL Peptide Drug CDMO Product
 Table 109. CBL Revenue in Peptide Drug CDMO Business (US$ Million), 2021–2026
 Table 110. CBL Recent Development
 Table 111. Piramal Pharma Company Details
 Table 112. Piramal Pharma Business Overview
 Table 113. Piramal Pharma Peptide Drug CDMO Product
 Table 114. Piramal Pharma Revenue in Peptide Drug CDMO Business (US$ Million), 2021–2026
 Table 115. Piramal Pharma Recent Development
 Table 116. CPC Scientific Company Details
 Table 117. CPC Scientific Business Overview
 Table 118. CPC Scientific Peptide Drug CDMO Product
 Table 119. CPC Scientific Revenue in Peptide Drug CDMO Business (US$ Million), 2021–2026
 Table 120. CPC Scientific Recent Development
 Table 121. Research Programs/Design for This Report
 Table 122. Key Data Information from Secondary Sources
 Table 123. Key Data Information from Primary Sources
 Table 124. Authors List of This Report


List of Figures
 Figure 1. Peptide Drug CDMO Picture
 Figure 2. Global Peptide Drug CDMO Market Size Comparison by Type (US$ Million), 2021–2032
 Figure 3. Global Peptide Drug CDMO Market Share by Type: 2025 vs 2032
 Figure 4. APIs and Intermediates Features
 Figure 5. FDF Features
 Figure 6. Global Peptide Drug CDMO Market Size by Application (US$ Million), 2021–2032
 Figure 7. Global Peptide Drug CDMO Market Share by Application: 2025 vs 2032
 Figure 8. Antineoplastic Drugs Case Studies
 Figure 9. Geno-Urinary System and Sex Hormones Case Studies
 Figure 10. Cardiovascular System Drugs Case Studies
 Figure 11. Anti-Infective Drugs Case Studies
 Figure 12. Peptide Drug CDMO Report Years Considered
 Figure 13. Global Peptide Drug CDMO Market Size (US$ Million), Year-over-Year: 2021–2032
 Figure 14. Global Peptide Drug CDMO Market Size, (US$ Million), 2021 vs 2025 vs 2032
 Figure 15. Global Peptide Drug CDMO Market Share by Region: 2025 vs 2032
 Figure 16. Global Peptide Drug CDMO Market Share by Players in 2025
 Figure 17. Global Peptide Drug CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
 Figure 18. The Top 10 and 5 Players Market Share by Peptide Drug CDMO Revenue in 2025
 Figure 19. North America Peptide Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
 Figure 20. North America Peptide Drug CDMO Market Share by Country (2021–2032)
 Figure 21. United States Peptide Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
 Figure 22. Canada Peptide Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
 Figure 23. Europe Peptide Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
 Figure 24. Europe Peptide Drug CDMO Market Share by Country (2021–2032)
 Figure 25. Germany Peptide Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
 Figure 26. France Peptide Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
 Figure 27. U.K. Peptide Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
 Figure 28. Italy Peptide Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
 Figure 29. Russia Peptide Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
 Figure 30. Ireland Peptide Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
 Figure 31. Asia-Pacific Peptide Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
 Figure 32. Asia-Pacific Peptide Drug CDMO Market Share by Region (2021–2032)
 Figure 33. China Peptide Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
 Figure 34. Japan Peptide Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
 Figure 35. South Korea Peptide Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
 Figure 36. Southeast Asia Peptide Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
 Figure 37. India Peptide Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
 Figure 38. Australia & New Zealand Peptide Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
 Figure 39. Latin America Peptide Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
 Figure 40. Latin America Peptide Drug CDMO Market Share by Country (2021–2032)
 Figure 41. Mexico Peptide Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
 Figure 42. Brazil Peptide Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
 Figure 43. Middle East & Africa Peptide Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
 Figure 44. Middle East & Africa Peptide Drug CDMO Market Share by Country (2021–2032)
 Figure 45. Israel Peptide Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
 Figure 46. Saudi Arabia Peptide Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
 Figure 47. UAE Peptide Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
 Figure 48. Bachem Revenue Growth Rate in Peptide Drug CDMO Business (2021–2026)
 Figure 49. PolyPeptide Revenue Growth Rate in Peptide Drug CDMO Business (2021–2026)
 Figure 50. CordenPharma Revenue Growth Rate in Peptide Drug CDMO Business (2021–2026)
 Figure 51. AmbioPharm Revenue Growth Rate in Peptide Drug CDMO Business (2021–2026)
 Figure 52. USV Peptides Revenue Growth Rate in Peptide Drug CDMO Business (2021–2026)
 Figure 53. Thermofischer Revenue Growth Rate in Peptide Drug CDMO Business (2021–2026)
 Figure 54. Bio Basic Revenue Growth Rate in Peptide Drug CDMO Business (2021–2026)
 Figure 55. JPT Revenue Growth Rate in Peptide Drug CDMO Business (2021–2026)
 Figure 56. Genscript Revenue Growth Rate in Peptide Drug CDMO Business (2021–2026)
 Figure 57. Xinbang Pharma Revenue Growth Rate in Peptide Drug CDMO Business (2021–2026)
 Figure 58. ScinoPharm Revenue Growth Rate in Peptide Drug CDMO Business (2021–2026)
 Figure 59. SN Biopharm Revenue Growth Rate in Peptide Drug CDMO Business (2021–2026)
 Figure 60. CBL Revenue Growth Rate in Peptide Drug CDMO Business (2021–2026)
 Figure 61. Piramal Pharma Revenue Growth Rate in Peptide Drug CDMO Business (2021–2026)
 Figure 62. CPC Scientific Revenue Growth Rate in Peptide Drug CDMO Business (2021–2026)
 Figure 63. Bottom-up and Top-down Approaches for This Report
 Figure 64. Data Triangulation
 Figure 65. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic

$2900

Single User License
Electronic

$4350

Multi User License
Electronic

$5800

Enterprise License
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Samsung SD